Within project ACHILLEUS, we develop a novel high-content drug screening platform. Our platform combines high throughput imaging of drug-treated, patient-derived organoids. Our groundbreaking approach integrates large-scale image-based screening with cutting-edge AI-based data processing and phenotypic data analysis. Our innovative knowledge base guides us in a data-driven way to identify new drug targets and develop drug candidates targeting critical vulnerabilities in cancer, particularly cancer stemness signaling. The stemness of neoplastic cells as the root cause of complications in cancer has been proposed as a major factor in treatment resistance and high relapse rates and is thus at the core of our mission to improve the lives of cancer patients. Using our biological insights, screening platform, and AI processing pipeline, we and our future partners aim to make AI-driven drug discovery a reality and bring new therapeutics to the market and, finally, to cancer patients in need.
Company Details
- Founded
- -
- Address
- Heidelberg, De
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.eic-achilleus.eu
- Keywords
- drug discovery, organoids, colorectal cancer.
- HQ
- Heidelberg
Reach Therapeutics I.gr. Questions
Reach Therapeutics I.Gr.'s website is http://www.eic-achilleus.eu
Reach Therapeutics I.Gr.'s LinkedIn profile is https://de.linkedin.com/company/eic-achilleus
Reach Therapeutics I.Gr.'s industry is
Biotechnology Research
Reach Therapeutics I.Gr.'s top competitors are
St Innovative Diagnostics Ltd.,
Mitophilix,
Aipto,
Metimedi Co., Ltd.,
Seal Biosciences,
St-Diagnostic,
Chess Therapeutics, Llc,
Glitther,
Synchrony,
Epigenetic Data Sciences.
Reach Therapeutics I.Gr.'s categories are Biotechnology Research
Reach Therapeutics I.Gr.'s founding year is 2025
